Verastem(VSTM) - 2025 Q4 - Earnings Call Presentation

Q4 & Full Year 2025 Earnings Call March 4, 2026 Disclaimers Forward-Looking Statements This presentation includes forward-looking statements about, among other things, Verastem Oncology's (the "Company") programs and product candidates, strategy, future plans and prospects, including statements related to the approval and commercialization of AVMAPKIFAKZYNJACO-PACK (avutometinib capsules; defactinib tablets) as a treatment for adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant-type ...